Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
about
Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the StriatumThe endocannabinoid system as an emerging target of pharmacotherapyPhosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical ImplicationsLower limb progressive resistance training improves leg strength but not gait speed or balance in Parkinson's disease: a systematic review and meta-analysisLevodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsTargeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Upregulation and axonal transport of synaptotagmin-IV in the direct-pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulationPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingMass spectrometry imaging, an emerging technology in neuropsychopharmacology.The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatmentEndogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in miceProteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialStriatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaConvergent evidence for abnormal striatal synaptic plasticity in dystonia.Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Cell-based therapies for Parkinson's disease: past, present, and futureNicotine from cigarette smoking and diet and Parkinson disease: a review.Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry.Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.Dopamine, affordance and active inference.Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.Transcriptome analysis in a rat model of L-DOPA-induced dyskinesiaNew treatments for the motor symptoms of Parkinson's disease.Clinical spectrum of levodopa-induced complications.Nonhuman primate models of Parkinson's disease.Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Preclinical assessment of stem cell therapies for neurological diseases.5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Critical aspects of clinical trial design for novel cell and gene therapies.Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine.Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells.The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated ratsModeling Parkinson's disease in primates: The MPTP model
P2860
Q21284508-4727749C-DBDD-460F-93F1-A078162634C6Q24648473-1C3E1DD7-1CFA-49F5-B93B-511E7A1FF604Q26753116-FB2BB579-C6E3-4B13-84EB-5EF26FD2B25BQ27016128-2A46967F-3AA1-4168-A207-E35C366C1863Q27316872-C71A359D-F9F7-4946-86A4-90961EF0A5FFQ27324174-397A4F3E-F053-42D8-8DC6-8A2C41289E66Q28115869-87A1CADC-A4CB-405B-8A10-DA828B5AE35BQ28582674-0BF9622D-E085-48A0-B3C3-4DE0A5382BA1Q30422058-1ED5F89B-EB76-45F5-8257-1AF6131C54F9Q30506209-13DCC301-FBCA-445F-BCD0-F7259163EA69Q30523813-913166E3-7DA2-4B6A-8769-1E09BFAF3FA5Q33285975-CB2BE133-2D1E-432B-B91A-FF4EFFA11881Q33290999-03535A54-7363-429B-9C04-C29A6595B006Q33319566-D3B71159-1BFD-4AB7-A60F-03AB1A1F55EAQ33725654-8A9A41F3-8F13-4B9E-A1C5-0985A2C5DF70Q33756951-3A1E2FE6-8007-4217-98BC-2D390F39EE52Q33807060-AFC26A52-EC17-47D0-9EDC-E96D6FA86938Q33818127-896D683D-3D30-484A-96FA-1494A0CCDC3BQ33862534-376EFFA9-9157-4581-83C1-8D46CADE3D66Q33931801-E15C8A57-0937-41D3-89F5-0C06DA84E00AQ33954124-55EC88A4-5BE1-452B-A14F-51B21C9D7479Q34044620-33847029-3311-4FED-AA9A-A0E41D9FECE5Q34105586-AC97E6E1-71A2-4694-BAF1-658CA6F21685Q34126224-B611EC1D-C095-4CE6-BFEB-27BC48E16084Q34165820-3CCB54C6-B487-4297-8E66-BC185394A2D8Q34400095-980E730A-6D02-444F-9276-69333EB6EAA1Q34443682-298AFA88-DB2B-440B-A1FE-1A68E4CD503DQ34452721-11DD709D-20D8-40DF-AA47-2D42D6B32949Q34665820-0EB9BA2B-2B73-4F82-A0B6-4A422EA0DE98Q34673205-508302AE-252D-4BB7-87B4-74F17A8E0031Q34786764-0FD23861-B83F-4868-BF32-AD2064E5E85EQ35015786-161D55A7-5D7F-448F-A9BD-17BB08F52159Q35499568-E1A1F518-0480-4430-A681-CC3B6F753BDDQ35589979-A646D14D-D9D7-45D2-9273-E4DE9539BF35Q35664438-AAEED37B-DF86-428A-9BF4-36B067CAAB69Q35669953-93C164C0-5EB8-4640-8DE0-63ED69941DB2Q35683102-775DF444-EFBC-4AEC-8C46-CF1130D29A61Q35732928-F3BE2596-2FDE-431C-8662-59B972484814Q35740152-215F6254-5146-4F16-B72A-7A7FD17F24D8Q35765748-D44FE307-60AC-40CA-B50A-D8E08CF86539
P2860
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@ast
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@en
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@nl
type
label
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@ast
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@en
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@nl
prefLabel
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@ast
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@en
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@nl
P2093
P2860
P921
P356
P1476
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
@en
P2093
P2860
P2888
P304
P356
10.1038/35086062
P407
P577
2001-08-01T00:00:00Z
P6179
1013971521